Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
Takeda posts surprise profit a year after Shire mega-mergerJapan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year Share XTakeda posts surprise profit a year after Shire mega-mergerhttps://pharmaphorum.com/news/takeda-posts-surprise-profit-a-year-after-shire-mega-merger/
Breadth versus depth in R&D managementTakeda’s Georgia Keresty is one of the only chief operating officers (COOs) for R&D in the industry. She Share XBreadth versus depth in R&D managementhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/breadth-versus-depth-in-r-and-d-management/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
Takeda eyes emerging markets asset sale to trim its debt; reportTakeda is said to be considering the sale of assets in emerging markets and western Europe to pay Share XTakeda eyes emerging markets asset sale to trim its debt; reporthttps://pharmaphorum.com/news/takeda-eyes-emerging-markets-asset-sale-to-trim-its-debt-report/
Case Study: How Shire improved its time-to-marketAdopting an end-to-end commercial content management system has allowed one of the world’s biggest pharmaceutical companies to be Share XCase Study: How Shire improved its time-to-markethttps://pharmaphorum.com/debates-insight-sales-marketing/case-study-how-shire-improved-its-time-to-market/
Takeda mulling sale of emerging market drugs – reportTakeda could be considering selling some emerging-market drugs in a bid to cut debts following its merger with Share XTakeda mulling sale of emerging market drugs – reporthttps://pharmaphorum.com/news/takeda-could-sell-emerging-market-drugs/
Takeda’s Shire takeover could herald new era of pharma M&ATakeda has officially taken over Shire in a deal that could re-establish the trend for mega mergers in Share XTakeda’s Shire takeover could herald new era of pharma M&Ahttps://pharmaphorum.com/news/takedas-shire-takeover-could-herald-new-era-of-pharma-ma/
Takeda unlikely to sell OTC unit to pay Shire merger debtsTakeda’s $59 billion takeover of Shire is due to close tomorrow (Tuesday) and the company’s CEO Christophe Weber Share XTakeda unlikely to sell OTC unit to pay Shire merger debtshttps://pharmaphorum.com/news/takeda-unlikely-to-sell-otc-unit-to-pay-shire-merger-debts/
